Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Medical Oncology
What systemic therapy would you suggest for metastatic odontogenic clear cell carcinoma with no actionable mutations on NGS?
Related Questions
What is the preferred neoadjuvant/adjuvant chemotherapy regimen for HPV-associated nasopharyngeal cancer?
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
Is there a scenario in which you would consider observation for T4a SCC involving the mandible?
How would the updated results of ECOG 3311 influence your adjuvant RT recommendations for HPV+ OPSCC?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
Do you regularly perform pharmacogenomic testing for patients prior to starting chemotherapy?
